InsidersTradesSigma
Track the IRIDEX CORP share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, IRIDEX CORP has recorded 144 reports. Market capitalisation: €13.2m. The latest transaction was disclosed on 24 August 2026 (Acquisition). Among the most active insiders: Dizon Romeo R. Every trade is accessible without an account.
144
Insider Decl.
n/a
Thresholds
€244,664
84 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate IRIDEX CORP Strong Buy (bullish), based on 1 analysts. Average price target: US$2.75.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,446 of 28,985 companies
16.2
score / 100
Value9
Quality24
FCF yld-18%
Earn yld-36%
EV/EBITDA·
ROE-73%
Gross mgn37%
Net mgn-8.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations144 total
1,300 shares@ US$0.7488Common StockSEC:0001193125-26-362654:0
Canonical exit: 22 Nov 2026 (T+90)
5,368 shares@ US$0.7499Commn StockSEC:0001193125-26-362654:1
Canonical exit: 22 Nov 2026 (T+90)
100,000 shares0Common StockSEC:0001193125-26-303346:0
30,000 shares0Common StockSEC:0001193125-26-303280:0
111,997 sharesCommon StockSEC:0002064835-26-000071:0
2,691 sharesCommon StockSEC:0001193125-26-273105:0
975 sharesCommon StockSEC:0001193125-26-270572:0
Canonical exit: 10 Sept 2026 (T+90)
2,400 sharesCommon StockSEC:0001193125-26-263083:0
Canonical exit: 6 Sept 2026 (T+90)
2,521 shares@ US$1.150.018% mcap35.4% of flowCommon StockSEC:0001193125-26-260846:0
Canonical exit: 3 Sept 2026 (T+90)
87,949 sharesCommon StockSEC:0002097627-26-000013:0
1,110 shares@ US$1.260.9% of flowCommon StockSEC:0001193125-26-098098:0
Canonical exit: 4 Jun 2026 (T+90)
1,000 shares@ US$1.370.9% of flowCommon StockSEC:0001193125-26-054026:0
Canonical exit: 18 May 2026 (T+90)
1,500 shares@ US$1.431.4% of flowCommon StockSEC:0001193125-26-047894:0
Canonical exit: 13 May 2026 (T+90)
1,000 shares@ US$1.460.9% of flowCommon StockSEC:0001193125-26-044507:0
Canonical exit: 11 May 2026 (T+90)
2,500 shares@ US$1.382.2% of flowCommon StockSEC:0001193125-26-036078:0
Canonical exit: 4 May 2026 (T+90)
1,101 shares@ US$1.4421.0% of flowCommon StockSEC:0001193125-26-029281:0
Canonical exit: 29 Apr 2026 (T+90)
1,300 shares@ US$1.461.2% of flowCommon StockSEC:0001193125-26-026809:0
Canonical exit: 28 Apr 2026 (T+90)
3,385 shares@ US$1.47993.2% of flowCommon StockSEC:0001193125-26-023871:0
Canonical exit: 27 Apr 2026 (T+90)
1,243 shares@ US$1.521.2% of flowCommon StockSEC:0001193125-26-021873:0
Canonical exit: 26 Apr 2026 (T+90)
5,221 shares@ US$1.47795.0% of flowCommon StockSEC:0001193125-26-020878:0
Canonical exit: 23 Apr 2026 (T+90)
2,100 shares@ US$1.49872.1% of flowCommon StockSEC:0001193125-26-017711:0
Canonical exit: 20 Apr 2026 (T+90)
227 shares@ US$1.380.2% of flowCommon StockSEC:0001193125-26-015491:0
Canonical exit: 16 Apr 2026 (T+90)
116,540 sharesCommon StockSEC:0002097627-26-000011:0
97,610 sharesCommon StockSEC:0002097627-26-000010:0
137,333 sharesCommon StockSEC:0002097627-26-000009:0
25 of 144 declarations
About IRIDEX CORP
IRIDEX Corporation (ticker: IRIX) is a U.S.-based ophthalmic medical technology company listed on Nasdaq in the United States, part of the NYSE/NASDAQ universe followed by global equity investors. The company was founded in 1989 as IRIS Medical Instruments, Inc., later renamed IRIDEX Corporation in 1996, and has long been associated with Silicon Valley. Its executive offices remain in Mountain View, California, although in February 2026 the company announced plans to relocate its headquarters to San Jose to lower operating costs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) IRIDEX focuses on the development, manufacturing, and commercialization of therapeutic laser systems, delivery devices, and single-use consumable instrumentation for ophthalmology. Its core addressable markets are glaucoma and retinal diseases, including diabetic macular edema (DME). Key product families include the Cyclo G6® laser system for glaucoma, the Iridex 532® and Iridex 577® lasers, and the proprietary MicroPulse® technology, which the company positions as a differentiated laser treatment designed to be safer and more tissue-sparing than conventional continuous-wave laser approaches. Consumable probes and delivery accessories are an important part of the product stack and help support recurring revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) From a competitive standpoint, IRIDEX is a niche specialist rather than a broad-line ophthalmic equipment conglomerate. Its investment case rests on clinical differentiation, installed base, and scientific validation, particularly around MicroPulse applications in glaucoma management and retinal therapy. That specialization can be an advantage in targeted indications where surgeons value precision, safety, and repeatability, but it also means the company operates in a competitive, innovation-driven market where reimbursement, adoption rates, and physician preference matter materially. ([iridex.gcs-web.com](https://iridex.gcs-web.com/news-releases/news-release-details/iridex-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai)) Geographically, the company sells primarily in the United States through a direct sales force, while international business is handled mainly through independent distributors. Its 2025 Form 10-K states that products were sold in the U.S. and Germany directly, and in other international markets via Topcon Corporation and additional distributors, including Italy, the U.K. (glaucoma), India, and smaller markets. The company also stated that its products are sold into more than 100 countries. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) Recent company developments have been noteworthy. In March 2026, IRIDEX reported full-year 2025 revenue of $52.7 million versus $48.7 million in 2024, while narrowing net loss to $4.4 million from $8.9 million. In 2025 and early 2026, it highlighted clinical publications supporting MicroPulse, launched a U.K. study in diabetic macular edema, appointed Patrick Mercer as CEO in October 2024, announced a strategic investment in March 2025, and disclosed its headquarters relocation plan in February 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm))
